|
| Status |
Public on Dec 30, 2014 |
| Title |
shRNA knockdown of YAP1 in HCC364 cells, various drug conditions |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Through a genetic screen in BRAF mutant tumor cells, we show that the Hippo pathway effector YAP acts as a parallel survival input to promote resistance to RAF-MEK inhibitor therapy. Our data uncover YAP as a novel mechanism of resistance to RAF-MEK targeted therapy. The findings unveil the synthetic lethality of YAP and RAF-MEK co-suppression as a promising strategy to enhance response and patient survival.
|
| |
|
| Overall design |
RNAseq analysis of HCC364 (lung adenocarcinoma) cells in the context of drug treatment with PLX4720 (vemurafenib, a BRAF inhibitor) or Trametinib (a MEK inhibitor) alongside shRNA knockdown of the gene YAP1
|
| |
|
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| Submission date |
Dec 29, 2014 |
| Last update date |
May 15, 2019 |
| Contact name |
Saurabh Asthana |
| E-mail(s) |
saurabh.asthana@ucsf.edu
|
| Organization name |
UCSF
|
| Department |
Helen Diller Family Comprehensive Cancer Center
|
| Lab |
Olshen
|
| Street address |
1450 Third Street, Room HD276
|
| City |
San Francisco |
| State/province |
CA |
| ZIP/Postal code |
94158 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
| Samples (9)
|
|
| Relations |
| BioProject |
PRJNA271287 |
| SRA |
SRP051595 |
Less...
More...